Results 221 to 230 of about 234,795 (273)

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy. [PDF]

Dermatol Ther (Heidelb)
Fratton Z, Bighetti S, Bettolini L, Venturini M, Rossi M, Carugno A, Zerbinati N, Stinco G, Errichetti E.   +8 more
europepmc   +1 more source

Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report. [PDF]

Case Rep Dermatol
Thomas KV, Tran JM, Cotter LM.
europepmc   +1 more source

Guselkumab for plaque psoriasis

, 2019
openaire   +1 more source

Deucravacitinib for plaque psoriasis

openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Plaque-type psoriasis inhibitors

International Immunopharmacology, 2021
Psoriasis is a common inflammatory skin disorder, which is mediated by the immune system and affects 1-4% of the world's population. Psoriasis is caused by a complex interaction between the immune system, autoantigens, psoriasis-associated genetic factors, and various environmental factors.
Saeideh Sadat Shobeiri, Motahareh Khorrami, Mojtaba Sankian   +2 more
openaire   +2 more sources

Guttate and Plaque Psoriasis

Dermatologic Clinics, 1995
Guttate and plaque psoriasis are regarded as variants of one disease but present with distinct clinical and histologic appearances. This article focuses special attention on different pathways in the development and clinical course of each, with emphasis on immunologic correlations regarding HLA system linkage and therefore genotypical expression.
E, Christophers, P, Kiene
openaire   +2 more sources